1.Analysis of in-service occupational medical examination results during employment for high-temperature workers in Longhua District, Shenzhen City
Fuling CAI ; Hongxin LV ; Zhiheng XU ; Shichen WU
China Occupational Medicine 2025;52(2):228-231
Objective To investigate the health status of high-temperature workers in Longhua District, Shenzhen City. Methods A total of 10 323 high-temperature workers in Longhua District from 2019 to 2022 were selected as the research subjects using the judgment sampling method. Their in-service occupational medical examination results during employment were collected and analyzed by grouping. Results The abnormal rates of urinalysis, blood pressure, serum alanine aminotransferase (ALT), electrocardiogram (ECG), and blood glucose among the research subjects were 34.9%, 12.5%, 8.5%, 7.6%, and 7.2%, respectively. Women had a higher rate of abnormal urinalysis than men (63.0% vs 25.9%, P<0.01), while men had higher rates of abnormal blood pressure and serum ALT than women (13.5% vs 9.4%, 10.2% vs 3.1%, both P<0.01). The abnormal rates of urinalysis, blood pressure, ECG, and blood glucose among the research subjects increased with age (all P<0.05), while the abnormal rate of serum ALT decreased with age (P<0.01). The abnormal rates of blood pressure and blood glucose increased with the length of high-temperature work time (all P<0.01). The most common occupation exposed to high temperatures was injection molding (accounting for 22.2%). The abnormal rates of urinalysis, blood pressure, serum ALT, ECG, and blood glucose among different occupations had significant differences (all P<0.01). Among them, injection molding workers had the highest rate of abnormal urinalysis (43.5%), while inflation film workers had the highest rate of abnormal blood pressure (24.2%). Conclusion The health status of high-temperature workers in Longhua District is concerning. Priority should be given to addressing abnormalities in urinalysis, ALT, ECG, blood pressure, and blood glucose. Occupational medical examinations should focus on elder workers and those with long high-temperature work time.
2.A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C
Lai WEI ; Jia SHANG ; Xuan AN ; Guoqiang ZHANG ; Yujuan GUAN ; Hongxin PIAO ; Jinglan JIN ; Lang BAI ; Xingxiang YANG ; Daokun YANG ; Xinhua LUO ; Shufang YUAN ; Yingren ZHAO ; Yingjie MA ; Guangming LI ; Feng LIN ; Xiaoping WU ; Jiawei GENG ; Guizhou ZOU ; Jiabao CHANG ; Zuojiong GONG ; Xiaorong MAO ; Jing ZHU ; Wentao GUO ; Qingwei HE ; Lin LUO ; Yulei ZHUANG ; Hongming XIE ; Yingjun ZHANG
Chinese Journal of Hepatology 2025;33(6):560-569
Objective:To assess the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of chronic hepatitis C (CHC) of various genotypes, without cirrhosis or with compensated cirrhosis.Methods:394 cases with CHC from 22 centers were collected from October 2021 to April 2023. They were randomly assigned to receive either the experimental drugs (antaitasvir phosphate 100 mg+yiqibuvir 600 mg) or placebo treatment in a 3∶1 ratio. The patients were administered drugs once a day for 12 consecutive weeks, and then followed up for 24 weeks after treatment cessation. All subjects were unblinded at the four-week follow-up following drug discontinuation, with the experimental drug group continuing to complete subsequent post-discontinuation follow-up. The placebo group was switched to receive the experimental drugs for a repeated 12-week treatment period and followed up for another 24 weeks after discontinuation of the drug (placebo delayed treatment phase).The sustained virologic response rate (SVR12) was observed for subjects in the double-blind phase and the placebo delayed-treatment phase at 12 weeks after treatment cessation.Virological resistance analysis was performed on subjects who failed treatment. The primary efficacy endpoint was SVR12. The number and percentage of subjects who achieved "HCV RNA
3.Analysis of Influential Factors on Chronic Disease Patients' Willingness to Participate in Home Pharmaceutical Care Based on Null Importance
Ke ZHAO ; Hongxin YANG ; Mingfen WU ; Hao GUO ; Zhigang ZHAO
Herald of Medicine 2025;44(8):1347-1351
Objective To investigate the key factors influencing the willingness of chronic disease patients to participate in home pharmaceutical services.Methods The study adopted the data from inner Mongolia and northeast China set of the drug aging system research for China.The Null Importance method was employed to identify key factors influencing the willingness of chronic disease patients to participate in home pharmaceutical services.The logistic regression model was constructed and evaluated the impact of feature selection through 5 fold cross-validation and accuracy and AUC values.Results 10 key factors were selected by the Null Importance method and the performance of the logistic regression model was improved after feature selection.The factors which significantly affected patients' willingness to accept home pharmaceutical services included the number of accessible information sources(OR=1.261,95%CI=1.182~1.345),medication therapeutic indication cognition(OR=1.342,95%CI=1.124~1.603),the presence the drug packaging or not(OR=1.218,95%CI=1.015~1.462),medication adherence(OR=0.881,95%CI=0.839~0.925),medication literacy(OR=0.631,95%CI=0.488~0.817),the degree of know of medication guidance services(OR=1.211,95%CI=1.017~1.442).Conclusion The logistic model refined by the Null Importance feature selection method demonstrated good performance and was conducive to analyzing the factors influencing the willingness of chronic disease patients to participate in home pharmaceutical care.
4.Development and validation of a clinical automatic diagnosis system based on diag-nostic criteria for temporomandibular disorders
Yuanyuan FANG ; Fan XU ; Jie LEI ; Hao ZHANG ; Wenyu ZHANG ; Yu SUN ; Hongxin WU ; Kaiyuan FU ; Weiyu MAO
Journal of Peking University(Health Sciences) 2025;57(1):192-201
Objective:To develop a clinical automated diagnostic system for temporomandibular disor-ders(TMD)based on the diagnostic criteria for TMD(DC/TMD)to assist dentists in making rapid and accurate clinical diagnosis of TMD.Methods:Clinical and imaging data of 354 patients,who visited the Center for TMD & Orofacial Pain at Peking University Hospital of Stomatology from September 2023 to January 2024,were retrospectively collected.The study developed a clinical automated diagnostic system for TMD using the DC/TMD,built on the.NET Framework platform with branching statements as its in-ternal structure.Further validation of the system on consistency and diagnostic efficacy compared with DC/TMD were also explored.Diagnostic efficacy of the TMD clinical automated diagnostic system for de-generative joint diseases,disc displacement with reduction,disc displacements without reduction with limited mouth opening and disc displacement without reduction without limited mouth opening was evalua-ted and compared with a specialist in the field of TMD.Accuracy,precision,specificity and the Kappa value were assessed between the TMD clinical automated diagnostic system and the specialist.Results:Diagnoses for various TMD subtypes,including pain-related TMD(arthralgia,myalgia,headache attribu-ted to TMD)and intra-articular TMD(disc displacement with reduction,disc displacement with reduc-tion with intermittent locking,disc displacement without reduction with limited opening,disc displace-ment without reduction without limited opening,degenerative joint disease and subluxation),using the TMD clinical automated diagnostic system were completely identical to those obtained by the TMD spe-cialist based on DC/TMD.Both the system and the expert showed low sensitivity for diagnosing degenera-tive joint disease(0.24 and 0.37,respectively),but high specificity(0.96).Both methods achieved high accuracy(>0.9)for diagnosing disc displacements with reduction and disc displacements without reduction with limited mouth opening.The sensitivity for diagnosing disc displacement without reduction without limited mouth opening was only 0.59 using the automated system,lower than the expert(0.87),while both had high specificity(0.92).The Kappa values for most TMD subtypes were close to 1,ex-cept the disc displacement without reduction without limited mouth opening,which had a Kappa value of 0.68.Conclusion:This study developed and validated a reliable clinical automated diagnostic system for TMD based on DC/TMD.The system is designed to facilitate the rapid and accurate diagnosis and classi-fication of TMD,and is expected to be an important tool in clinical scenarios.
5.Risk factors and construction of prediction model for neonatal pneumonia
Ruiyuan QIAN ; Wei WU ; Yajuan LU ; Hongxin LI
Chinese Journal of Nosocomiology 2025;35(11):1670-1673
OBJECTIVE To analyze the risk factors of neonatal pneumonia(NP)and construct the risk prediction model for NP.METHODS A total of 60 cases of neonatal pneumonia admitted to neonatology department of Chan-gzhou Children's Hospital from Dec.2022 to Dec.2023 were selected in the study group,and another 60 healthy neonates during the same period were randomly selected as the healthy group.The risk factors of neonatal pneu-monia were summarized by logistic regression analysis,the prediction model was established,the discrimination of the model was evaluated by receiver's operating characteristic(ROC)curves,and the correction capability was as-sessed by Hosmer-Lemeshow test.RESULTS Birth 1 min Apgar score<7 points(OR=5.930,95%CI:2.877-12.222,P<0.001)and amniotic fluid pollution(OR=4.175,95%CI:1.251-13.935,P=0.021)were the risk factors for neonatal pneumonia,while prophylactic antimicrobial drug application(OR=0.471,95%CI:0.226-0.982,P=0.044)was a protective factor(P<0.05).Based on the results of Logistic regression analysis,the formula of the relevant risk prediction model was established as logit(P)=20.780×1 min Apgar score-23.429 × amniotic fluid pollution+3.024 × prophylactic use of antibiotics+1.056.The results of ROC curves analysis showed that AUC of the risk prediction model was 0.774(95%CI:0.691-0.857),suggesting that the risk pre-diction model had a good discrimination,and Hosmer-Lemeshow x2=7.028,P=0.941,and there was good cali-bration degree of the model.CONCLUSION Birth 1 min Apgar score<7 points and amniotic fluid pollution are in-dependent risk factors of NP,while prophylactic antimicrobial drug application is a protective factor,and the risk prediction model for the development of NP based on logistic regression analysis had good predictive efficiency and accuracy.
6.Risk factors and construction of prediction model for neonatal pneumonia
Ruiyuan QIAN ; Wei WU ; Yajuan LU ; Hongxin LI
Chinese Journal of Nosocomiology 2025;35(11):1670-1673
OBJECTIVE To analyze the risk factors of neonatal pneumonia(NP)and construct the risk prediction model for NP.METHODS A total of 60 cases of neonatal pneumonia admitted to neonatology department of Chan-gzhou Children's Hospital from Dec.2022 to Dec.2023 were selected in the study group,and another 60 healthy neonates during the same period were randomly selected as the healthy group.The risk factors of neonatal pneu-monia were summarized by logistic regression analysis,the prediction model was established,the discrimination of the model was evaluated by receiver's operating characteristic(ROC)curves,and the correction capability was as-sessed by Hosmer-Lemeshow test.RESULTS Birth 1 min Apgar score<7 points(OR=5.930,95%CI:2.877-12.222,P<0.001)and amniotic fluid pollution(OR=4.175,95%CI:1.251-13.935,P=0.021)were the risk factors for neonatal pneumonia,while prophylactic antimicrobial drug application(OR=0.471,95%CI:0.226-0.982,P=0.044)was a protective factor(P<0.05).Based on the results of Logistic regression analysis,the formula of the relevant risk prediction model was established as logit(P)=20.780×1 min Apgar score-23.429 × amniotic fluid pollution+3.024 × prophylactic use of antibiotics+1.056.The results of ROC curves analysis showed that AUC of the risk prediction model was 0.774(95%CI:0.691-0.857),suggesting that the risk pre-diction model had a good discrimination,and Hosmer-Lemeshow x2=7.028,P=0.941,and there was good cali-bration degree of the model.CONCLUSION Birth 1 min Apgar score<7 points and amniotic fluid pollution are in-dependent risk factors of NP,while prophylactic antimicrobial drug application is a protective factor,and the risk prediction model for the development of NP based on logistic regression analysis had good predictive efficiency and accuracy.
7.Analysis of Influential Factors on Chronic Disease Patients' Willingness to Participate in Home Pharmaceutical Care Based on Null Importance
Ke ZHAO ; Hongxin YANG ; Mingfen WU ; Hao GUO ; Zhigang ZHAO
Herald of Medicine 2025;44(8):1347-1351
Objective To investigate the key factors influencing the willingness of chronic disease patients to participate in home pharmaceutical services.Methods The study adopted the data from inner Mongolia and northeast China set of the drug aging system research for China.The Null Importance method was employed to identify key factors influencing the willingness of chronic disease patients to participate in home pharmaceutical services.The logistic regression model was constructed and evaluated the impact of feature selection through 5 fold cross-validation and accuracy and AUC values.Results 10 key factors were selected by the Null Importance method and the performance of the logistic regression model was improved after feature selection.The factors which significantly affected patients' willingness to accept home pharmaceutical services included the number of accessible information sources(OR=1.261,95%CI=1.182~1.345),medication therapeutic indication cognition(OR=1.342,95%CI=1.124~1.603),the presence the drug packaging or not(OR=1.218,95%CI=1.015~1.462),medication adherence(OR=0.881,95%CI=0.839~0.925),medication literacy(OR=0.631,95%CI=0.488~0.817),the degree of know of medication guidance services(OR=1.211,95%CI=1.017~1.442).Conclusion The logistic model refined by the Null Importance feature selection method demonstrated good performance and was conducive to analyzing the factors influencing the willingness of chronic disease patients to participate in home pharmaceutical care.
8.A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C
Lai WEI ; Jia SHANG ; Xuan AN ; Guoqiang ZHANG ; Yujuan GUAN ; Hongxin PIAO ; Jinglan JIN ; Lang BAI ; Xingxiang YANG ; Daokun YANG ; Xinhua LUO ; Shufang YUAN ; Yingren ZHAO ; Yingjie MA ; Guangming LI ; Feng LIN ; Xiaoping WU ; Jiawei GENG ; Guizhou ZOU ; Jiabao CHANG ; Zuojiong GONG ; Xiaorong MAO ; Jing ZHU ; Wentao GUO ; Qingwei HE ; Lin LUO ; Yulei ZHUANG ; Hongming XIE ; Yingjun ZHANG
Chinese Journal of Hepatology 2025;33(6):560-569
Objective:To assess the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of chronic hepatitis C (CHC) of various genotypes, without cirrhosis or with compensated cirrhosis.Methods:394 cases with CHC from 22 centers were collected from October 2021 to April 2023. They were randomly assigned to receive either the experimental drugs (antaitasvir phosphate 100 mg+yiqibuvir 600 mg) or placebo treatment in a 3∶1 ratio. The patients were administered drugs once a day for 12 consecutive weeks, and then followed up for 24 weeks after treatment cessation. All subjects were unblinded at the four-week follow-up following drug discontinuation, with the experimental drug group continuing to complete subsequent post-discontinuation follow-up. The placebo group was switched to receive the experimental drugs for a repeated 12-week treatment period and followed up for another 24 weeks after discontinuation of the drug (placebo delayed treatment phase).The sustained virologic response rate (SVR12) was observed for subjects in the double-blind phase and the placebo delayed-treatment phase at 12 weeks after treatment cessation.Virological resistance analysis was performed on subjects who failed treatment. The primary efficacy endpoint was SVR12. The number and percentage of subjects who achieved "HCV RNA
9.Comparison of robotic natural orifice specimen extraction surgery and robotic-assisted surgery for radical resection of rectal cancer: a propensity score matching study
Shanping YE ; Hongxin YU ; Huiyu HU ; Dongning LIU ; Can WU ; Ruixiang ZOU ; Penghui HE ; Taiyuan LI
Chinese Journal of Gastrointestinal Surgery 2024;27(8):833-839
Objective:To compare the surgical outcomes of robotic natural orifice specimen extraction surgery (NOSES) and robotic-assisted radical resection for rectal cancer.Methods:A retrospective analysis using propensity score matching (PSM) was conducted on 547 patients who had undergone radical resection of rectal cancer at the First Affiliated Hospital of Nanchang University from June 2018 to March 2024. The study cohort comprised 157 patients in the robotic NOSES group and 390 in the robotic-assisted group. PSM was used in a 1:1 manner to match relevant general clinical preoperative data of the study patients (age, sex, body mass index, preoperative comorbidities, abnormal preoperative carcinoembryonic antigen (>6.5 μg/L) and carbohydrate antigen 19-9 levels (>27 kU/L), preoperative American Society of Anesthesiologists score, tumor diameter, tumor distance from the anal margin, and TNM stage), with a clamp value of 0.05. After performing PSM to match the general clinical data of the two groups of patients, 77 patients in each of the robotic NOSES and robotic-assisted groups were included in the analysis. We found no statistically significant difference in preoperative general clinical data between the robot NOSES and robot-assisted groups ( P>0.05). We compared the surgical outcomes, postoperative recovery, postoperative pathological data, and incidence of complications between the robotic NOSES and robot-assisted groups. Results:Compared with the robot-assisted groups. the robot NOSES group had a significantly shorter time to first postoperative passage of flatus (48 [38, 50] hours vs. 56 [50, 60] hours, Z=-7.513, P<0.001), time to taking a liquid diet (60 [54,63] hours vs. 66 [62, 72] hours, Z=-6.303, P<0.001), lower pain scores (3 [3, 4] vs. 4 [4, 5], Z=-5.237, P<0.001), and lower incision infection rates (0 vs. 5 [6.5%], χ 2=5.237, P=0.028) within 24 hours after surgery ( P<0.05). However, there were no significant differences in surgical time, intraoperative blood loss, postoperative hospital stay, postoperative anastomotic complications, or incidence of other complications between the two groups (all P>0.05). Conclusion:Robotic NOSES surgery is a safe and feasible procedure for resecting rectal cancer and postoperative recovery is faster after robotic NOSES than after standard robot-assisted surgery.
10.Prognosis and its influencing factors for premature infants complicated by twin-twin transfusion syndrome and born at ≤34 weeks' gestation
Tengyue ZHANG ; Haiyan WU ; Xinyue MO ; Hongxin WANG ; Wenxu PAN ; Yijuan LI ; Yuefang HUANG
Chinese Journal of Perinatal Medicine 2024;27(2):96-105
Objective:To investigate the perinatal prognosis and its impact factors for premature infants with twin-twin transfusion syndrome (TTTS) who were born at ≤34 weeks of gestation.Methods:A retrospective study was conducted on 68 pregnancies of TTTS with gestational age ≤34 weeks at delivery, among them 106 preterm infants (TTTS group) were admitted to the neonatal intensive care unit of the First Affiliated Hospital, Sun Yat-sen University from January 2003 to February 2019. During the same period, another 178 twins without TTTS, congenital malformation, and intrauterine intervention who matched the TTTS group in maternal age (differences within two years) and gestational age (differences within one week) were assigned as non-TTTS group. Perinatal prognosis of TTTS infants born at ≤34 weeks was analyzed by comparing the differences in postnatal early complications and perinatal outcomes (survival time morn than 28 days or not) between the TTTS and non-TTTS groups, recipient and donor twins, mild and severe TTTS infants, and among TTTS infants with different intrauterine interventions. The risk factors for perinatal survival in TTTS infants with gestational age ≤34 weeks were analyzed. Two independent samples t-test, one-way analysis of variance, rank-sum test, Chi-square test, and ordered logistic regression were used for statistical analysis. Results:(1) Among the 68 pregnancies, the overall perinatal survival rate of the neonates was 72.1% (98/136), the double-twin survival rate was 48.5% (33/68), and the rate of at least one survivor was 95.6% (65/68). (2) In the TTTS group, 62 were recipients and 44 were donors. Stage Ⅰ-Ⅱ TTTS was found in 41 cases (mild TTTS group) and stage Ⅲ-Ⅴ in 65 cases (severe TTTS group). (3) The rate of severe brain injury was higher in the severe-TTTS group than those in the mild-TTTS group [9.2% (6/65) vs. 0.0% (0/41), χ 2=4.01, P=0.045]. (4) Gestational age ≤28 weeks ( OR=101.90, 95% CI: 5.07-2 048.37), stage Ⅳ ( OR=14.04, 95% CI: 1.56-126.32) and stage Ⅴ TTTS ( OR=51.09, 95% CI: 3.58-728.81) were independent risk factors for death within 28 days (all P<0.05). (5) Compared with the non-TTTS group, the TTTS group had higher rates of neonatal anemia [51.9% (55/106) vs. 33.1% (59/178), χ 2=9.71], polycythemia [5.7% (6/106) vs. 0.6% (1/178), χ 2=7.18], neonatal persistent pulmonary hypertension [3.8% (4/106) vs. 0.0% (0/178), χ 2=6.81], sepsis [15.1% (16/106) vs. 7.3% (13/178), χ 2=4.40], state Ⅲ or higher retinopathy of prematurity [3.8% (4/106) vs. 0.0% (0/178), χ 2=6.81], congenital cardiac structural abnormality [19.8% (21/106) vs. 0.6% (1/178), χ 2=33.45], heart failure [8.5% (9/106) vs. 0.6% (1/178), χ 2=12.29], and renal insufficiency [14.2% (15/106) vs. 1.1% (2/178), χ 2=20.04] (all P<0.05). Conclusions:Compared with the twin premature infants without TTTS, those with TTTS and ≤34 gestational age were more likely to have cardiac, cerebral, and renal complications. The more severe the TTTS, the higher the incidence of severe brain injury. TTTS preterm infants with gestational age ≤28 weeks and stage Ⅳ or above have high risk of death.

Result Analysis
Print
Save
E-mail